Business Standard

Strides Shasun receives tentative approval for Roflumilast Tablets

Image

Capital Market

From USFDA

Strides Shasun announced that it has received tentative approval from the USFDA for Roflumilast Tablets, 500 mcg. The product received approval in 15 months under the new GDUFA goal date regime. The product can be launched earliest by January 2020.

Powered by Capital Market - Live News

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jun 01 2016 | 12:42 PM IST

Explore News